Encompass Health (EHC)
(Delayed Data from NYSE)
$84.49 USD
-0.06 (-0.07%)
Updated May 24, 2024 04:00 PM ET
After-Market: $84.46 -0.03 (-0.04%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$84.49 USD
-0.06 (-0.07%)
Updated May 24, 2024 04:00 PM ET
After-Market: $84.46 -0.03 (-0.04%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Zacks News
Inogen (INGN) Stock Loses 26.7% In Spite of Q2 Earnings Beat
by Zacks Equity Research
Inogen's (INGN) second-quarter results benefit from higher revenues across its segments.
LHC Group (LHCG) Stock Loses 11.9% Despite Q2 Earnings Beat
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from organic growth in both home health and hospice admissions.
Abiomed's (ABMD) Q1 Earnings and Revenues Beat, Margins Up
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
BD (BDX) Beats on Q3 Earnings and Revenues, Ups '21 View
by Zacks Equity Research
Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal third quarter, thus driving up the overall top line.
Surmodics' (SRDX) Q3 Earnings, Revenues Fall Shy of Estimates
by Zacks Equity Research
Higher revenues from the IVD segment drives Surmodics' (SRDX) fiscal third-quarter top line.
New Strong Buy Stocks for August 5th
by Zacks Equity Research
ARCB, EHC, MRO, TTMI, and ON have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2021.
Tandem Diabetes (TNDM) Q2 Earnings Rise Y/Y, Sales View Up
by Zacks Equity Research
Tandem Diabetes (TNDM) reports better-than-expected revenues for second quarter 2021 on strong domestic and international pump shipments driving the top line.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Grow
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the second quarter with strong performance in Home Health and Hospice segments.
Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected
by Zacks Equity Research
Strength in both coronary and peripheral segments drove Cardiovascular Systems' (CSII) revenues in the fiscal fourth quarter.
Globus Medical (GMED) Q2 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Pull-through from robotics, contributions from new product introductions and resurgence in the Globus Medical's (GMED) biologics business drove second-quarter growth.
Cardinal Health (CAH) Q4 Earnings Lag, Revenues Top Estimates
by Zacks Equity Research
Although Cardinal Health (CAH) witnessed margin contraction in its fiscal fourth-quarter results, rise in revenues in both its segments is encouraging.
DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results benefit from strong segmental performance.
Change Healthcare (CHNG) Q1 Earnings Miss, Revenues Beat
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2022 results benefit from strong performance across all segments.
Zacks.com featured highlights include: Encompass Health, ON Semiconductor, Kimco Realty, LKQ Corp and Saia
by Zacks Equity Research
Zacks.com featured highlights include: Encompass Health, ON Semiconductor, Kimco Realty, LKQ Corp and Saia
DaVita (DVA) Beats on Q2 Earnings, Raises 2021 EPS View
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.
PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.
CVS Health (CVS) Q2 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
CVS Health (CVS) Q2 adjusted EPS drops year over year on escalating costs and expenses which are putting pressure on margins.
Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.
Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.
5 Best Stocks With Upgraded Broker Ratings Worth Investing In
by Swayta Shah
By following broker ratings upgrades, you can easily find attractive and profitable stocks. So, we choose Encompass Health (EHC), ON Semiconductor (ON), Kimco Realty (KIM), LKQ Corporation (LKQ) and Saia (SAIA) as these have witnessed ratings upgrade.
AmerisourceBergen (ABC) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.
Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Zimmer Biomet (ZBH) sales improve across all its operating segments and geographies on recovery from the pandemic in the months of the second quarter.
Henry Schein (HSIC) Q2 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the second quarter.